FDA: Ranbaxy's Lipitor safe for patients; CBO determines Medicare drug use cuts medical services costs

@FiercePharma: Russia's OTC drug market to grow by 11.5% by 2016, consultants say. Now at $16.4B. News | Follow @FiercePharma

> The FDA says Ranbaxy Laboratories' copy of Lipitor is safe for patients to take, after reviewing information from the company; last week, Ranbaxy recalled some lots because of potential contamination with glass particles. Report

> A Congressional Budget Office report concludes that a 1% increase in filled Medicare prescriptions yields a decline in spending on medical services. Report

> Most teens with mental disorders aren't treated with prescription drugs, a National Institutes of Health study found, quelling some fears about the overprescribing of psychotropic meds in youngsters. Report

> Johnson & Johnson's ($JNJ) settlement with Australian patients who received faulty knee implants won court approval, with compensation set at a minimum of $31,000 per patient. Report

> India's Aurobindo Pharma is set for FDA approval on a new plant in Hyderabad, the Economic Times reports. Report

> A derivative of vitamin B-5 sold as a cholesterol fighter in Japan may be useful in patients who can't tolerate the side effects of prescription drugs that lower cholesterol levels. Report (sub. req.)

Medical Device News

 @FierceMedDev: Volcano snags Crux Biomedical for $36M. Story | Follow @FierceMedDev

@MarkHFierce: Sorin gained approval in Japan for a new heart valve--a huge win and market. Release | Follow @MarkHFierce

 @DamianFierce: And there's the biggest deal of the year in devices: Baxter says it's buying Gambro for $4 billion. News | Follow @DamianFierce

> Add 'heart monitor' to the iPhone's many uses. Report

> Merit dives back into M&A with buy of catheter maker. Item

Biotech News

 @FierceBiotech: Synthetic compound halts Alzheimer's neurodegeneration in mice. More | Follow @FierceBiotech

 @JohnCFierce: If the court really does scrap off-label rules, I'm sure all the reps will carefully observe all proprieties, stay conservative (oh, yeah). | Follow @JohnCFierce

 @RyanMFierce: Nice analysis on pediatric drug dev. situation in U.S. from Bloomberg. Should industry cure kids first? News | Follow @RyanMFierce

> Big Pharma earns mixed grades on late-stage drug development report card. Story

> Flexion banks $20M VC round, shifts focus to late-stage osteoarthritis drugs. Article

> Geron axes dozens of staffers after careening into another trial flop. Report

Pharma Manufacturing News

> NextPharma unloads U.S. manufacturing arm, Bioserv. Report

> Sandoz India development center loses in realignment. News

> Protein Sciences takes over fully equipped Wyeth vaccine plant. Story

> Neopharma to produce Merck Serono branded meds in Middle East. Article

Biotech Research News

> Synthetic compound halts Alzheimer's neurodegeneration in mice. More

> MGH/Harvard drug treats Huntington's in 2 mouse studies. Article

> Stem cells from blood may be more patient-friendly. Story

> Amgen antibody combats obesity, diabetes in monkeys. News

And Finally... A dose of empathy from their doctors can help patients tolerate pain, a study finds. Report

 

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.